Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some big icebergs at .70.
Correct, Advent is the most advanced CDMO in the UK. This is great news for NWBO as Advent will be manufacturing their product for the UK/EU and maybe more.
Advent Bioservices is now the most advanced CDMO in the UK, servicing $NWBO and now checking all license boxes for GMP Manufacturing: MIA, MIA(IMP), MS, HTA, and GMO. #DCVax-L
— Henry (@HenryMuney) March 22, 2023
1. https://t.co/n5vIduWjKX
2. https://t.co/UdgwviriVO pic.twitter.com/NqLCp8I0oc
It's 2023. Lots of things have changed.
Have a good one LC!
Virtu's lengthy history of lax oversight might be very helpful for NWBO's lawsuit:
Sounds like @VirtuFinancial played loose with their required oversight per $NWBO's First Amended Complaint and the SEC's recent lawsuit. We have a pattern of behavior that goes back years with @VirtuFinancial $NWBO's First Amended Complaint:
— hoffmann6383 (@hoffmann6383) September 12, 2023
"...as registered broker-dealers,…
He did link us this great article yesterday thinking it was negative until he actually read the words of the article. ;)
$NWBO
— hoffmann6383 (@hoffmann6383) September 12, 2023
Dr. Prins says the team’s findings, “Suggest that enhancing the activation and presentation of T cells by dendritic cells could be a potential treatment strategy.”
Hello #DCVax-L 👋 https://t.co/WuOHfejq1C pic.twitter.com/wnuuwaewCl
Can you let us know the cause of action? I'm not familiar with the statute where you are not allowed to use someone elses own words to make them look like the piece of shit that they are.
The obligatory Poor Man tag line:
Yep and this is what can happen when you have a single entity acting as both a HF and MM:
https://www.sec.gov/litigation/litreleases/lr-25827
Their "walls" are illusory
☑️I believe Dr. Liau is there to help develop $NWBO's pipeline.
— hoffmann6383 (@hoffmann6383) September 12, 2023
☑️I believe the development of the pipeline starts with the combo trials referenced in the recent Q2 '23 10-Q.
☑️I believe Dr. Liau's involvement gives a level of comfort to a future combo trial partner.
"We are… pic.twitter.com/byWfNZMoVo
good stuff. thanks for sharing.
Are you saying once you crossed over to the rGBM arm you received chemo-rad? This would be false. Look at the trial protocol. If you need additional explanation please let me know. I'd be happy to help clarify further.
I'm not disagreeing she is looking for favorable terms. Please reread my post. I don't feel like getting in another flipper spat today. I have real work to do. My last response to what you will likely turn into a long drawn out pissing contest.
Have a good one Flipper. Enjoy the good Dr. Liau news.
Correct, there was no chemo/radiation for the rGBM arm, as I stated prior. As we all know, there is no SoC for rGBM.
Have a good one ex. by.
I'm not sure there will be a huge upfront payment to NWBO as related to the combo trials. I think there will be just enough funds at certain milestones to complete the trials. I'm hopeful that any initial upfront funds will at least get us to DCVax-L commercialization for nGBM/rGBM. I believe the big money comes later in a buyout. Or, as related to the share price, once it becomes apparent that DCVax-L is to be adopted as the SoC, the revenues start flowing and the general market realizes the enormous potential market for DCVax-L (all solid tumors). just my opinion
Marty,
You do great work in always trying to find the negative with such positive news.
Keep it up my friend.
It's almost like you get angry when the share price goes up. Strange reaction by a "long".
I like your list. I posted this comment elsewhere:
I would think Dr. Liau would not want to tie herself to one company (or appear to do so) as she is the head of UCLA neurosurgery and they probably get funding from a LOT of BP for trials/research. When you tie yourself with one company and maybe that company competes or overlaps with another company's research, UCLA is potentially cutting off a lot of research money. Dr. Liau has to know there is some big research project coming as related to NWBO. Otherwise, why tie yourself so publicly to one entity?
You make me want to like your posts, but knowing you are a fickle trader and can turn on a dime I'll refrain.
It almost sounds like LL will be potentially developing the IND for the upcoming combo trials. Or, at least have a big hand in said design.
Submission is happening. Then we will see the fud narrative shift after yet another milestone is checked off.
https://nwbio.com/northwest-biotherapeutics-announces-completion-of-prerequisites-and-plans-for-submission-of-marketing-authorization-application/
I'd recommend not getting advice from this person. We see ever shifting negative narratives that each bear to be false over time. We also have wild share price predictions:
If you call getting RA approval as 'taking a backseat' then I agree.
yep, dcvax-l has the potential to interrupt a lot of current revenue streams
Yeah, he has had some good posts on this subject in the past.
Good points Doc Lee. I'm far from a medical expert but from what little I've read the SoC treatment seems to work against DCVax-L. Having no SoC in rGBM might have helped along these outstanding preliminary results in the DCVax-L/ poly-iclc/ keytruda rGBM trial.
I think you're right. We have seen some unpublished data for keytruda/poly-iclc/ dcvax-l in rGBM
I agree - for rGBM. I wouldn't be surprised seeing this same combo used in a basket trial for all indications beyond the rGBM trial where we have already seen the outstanding data.
What are you talking about? Yesterday you said there were no such things as naked shorts. It's hard to keep track of these ever shifting narratives.
Reread the UCLA PR. They use DCVax-L. Or, listen to Dr. Liau state the same:
https://drive.google.com/file/d/1HMQSThmDpZdpUl3EDB1mD42rIdi3nhWg/view?usp=drivesdk
Thanks for linking a positive DCVax-L article. Exciting future. UCLA is probably going to be involved with additional NWBO combo trials.
credit to Learningcurve2020:
$NWBO
— hoffmann6383 (@hoffmann6383) September 12, 2023
Dr. Prins says the team’s findings, “Suggest that enhancing the activation and presentation of T cells by dendritic cells could be a potential treatment strategy.”
Hello #DCVax-L 👋 https://t.co/WuOHfejq1C pic.twitter.com/wnuuwaewCl
Great quote in there:
Thermo did what? Why don't you tag him if you are going to make up narratives about other investors. There is a new function on here where you can tag users. Feel free to do so.